JonesTrading Cuts Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00

Trevi Therapeutics (NASDAQ:TRVI) had its price target reduced by research analysts at JonesTrading from $25.00 to $24.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. JonesTrading’s price target would suggest a potential upside of 124.11% from the company’s current price.

Several other equities research analysts also recently issued reports on the stock. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday, March 9th. D. Boral Capital reiterated a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research note on Wednesday. Needham & Company LLC lifted their price target on Trevi Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday, March 9th. Finally, Leerink Partners upped their price objective on Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $21.60.

Trevi Therapeutics Trading Up 0.2%

Shares of NASDAQ:TRVI traded up $0.02 on Thursday, hitting $10.71. The company had a trading volume of 808,062 shares, compared to its average volume of 1,376,696. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -33.47 and a beta of 0.94. The stock has a 50 day moving average price of $11.15 and a 200 day moving average price of $10.93. Trevi Therapeutics has a 1-year low of $4.85 and a 1-year high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. Sell-side analysts anticipate that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of Trevi Therapeutics by 20.4% in the 1st quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock valued at $174,000 after acquiring an additional 4,688 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Trevi Therapeutics by 31.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock worth $278,000 after acquiring an additional 10,445 shares during the last quarter. Millennium Management LLC increased its holdings in Trevi Therapeutics by 356.3% in the 1st quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock worth $5,178,000 after purchasing an additional 642,830 shares in the last quarter. Strs Ohio acquired a new position in Trevi Therapeutics in the 1st quarter worth about $52,000. Finally, Geode Capital Management LLC raised its position in Trevi Therapeutics by 10.6% in the second quarter. Geode Capital Management LLC now owns 1,786,845 shares of the company’s stock valued at $9,776,000 after purchasing an additional 171,980 shares during the last quarter. 95.76% of the stock is owned by institutional investors.

Key Stories Impacting Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: FDA alignment: Trevi received End-of-Phase-2 alignment from the FDA and plans two pivotal Phase 3 trials for idiopathic pulmonary fibrosis (IPF)-related chronic cough — a major de‑risking step that supports future value if trials succeed. Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA
• Positive Sentiment: Q4 beat and business update: Trevi reported EPS of ($0.06) vs. consensus ~($0.10) for Q4 2025 and reiterated the Phase 3 program and other strategic updates on the earnings call and press release — an earnings beat that reduces near-term execution risk. Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results
• Positive Sentiment: Analyst bullish moves: Needham raised its price target from $22 to $24 (buy), signaling improved long‑term upside expectations tied to the Phase 3 program. Needham price target raise
• Positive Sentiment: HC Wainwright maintains Buy and modeled multi‑quarter EPS path: HC Wainwright reiterated a Buy and published quarterly EPS forecasts for 2026–2026 while projecting FY2030 upside — analyst modeling that supports higher targets if clinical progress continues. HC Wainwright estimates (MarketBeat)
• Positive Sentiment: D. Boral Capital reaffirmed buy with a $19 target, another vote of confidence from the sellside. D. Boral Capital reaffirmation
• Neutral Sentiment: Morgan Stanley adjustment: Morgan Stanley trimmed its price target from $19 to $18 but kept an “overweight” rating — a modest calibration that still implies upside but tempers some enthusiasm. Morgan Stanley target adjustment
• Neutral Sentiment: Recent coverage & valuation pieces are running alongside the clinical news — analysts and outlets are recalculating valuation given Phase 3 alignment, which can amplify intraday swings as investors reassess probabilities. Valuation after FDA green light (Yahoo)
• Negative Sentiment: Market reaction & liquidity: Despite the favorable clinical and earnings news, shares are trading marginally lower on lighter-than-average intraday volume and mixed analyst signals — suggesting near‑term profit‑taking and that some investors are waiting for clearer Phase 3 design/ timelines before committing. MarketBeat intraday/volume summary

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.